Symbols / IOVA
IOVA Chart
About
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.50B |
| Enterprise Value | 1.31B | Income | -390.98M | Sales | 263.50M |
| Book/sh | 1.70 | Cash/sh | 0.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -12.43 | PEG | — |
| P/S | 5.69 | P/B | 2.23 | P/C | — |
| EV/EBITDA | -3.62 | EV/Sales | 4.97 | Quick Ratio | 2.74 |
| Current Ratio | 3.20 | Debt/Eq | 7.08 | LT Debt/Eq | — |
| EPS (ttm) | -1.19 | EPS next Y | -0.30 | EPS Growth | — |
| Revenue Growth | 17.70% | Earnings | 2026-05-07 | ROA | -27.30% |
| ROE | -55.50% | ROIC | — | Gross Margin | 34.28% |
| Oper. Margin | -84.66% | Profit Margin | -148.38% | Shs Outstand | 396.97M |
| Shs Float | 351.42M | Short Float | 28.61% | Short Ratio | 8.36 |
| Short Interest | — | 52W High | 5.88 | 52W Low | 1.64 |
| Beta | — | Avg Volume | 11.14M | Volume | 69.37M |
| Target Price | $9.22 | Recom | Buy | Prev Close | $2.89 |
| Price | $3.78 | Change | 30.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.22
Mean price target
2. Current target
$3.78
Latest analyst target
3. DCF / Fair value
$-10.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.78
Low
$2.00
High
$16.00
Mean
$9.22
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | Barclays | Overweight → Overweight | $10 |
| 2025-11-24 | main | Barclays | Overweight → Overweight | $9 |
| 2025-11-06 | main | Chardan Capital | Buy → Buy | $17 |
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-08-08 | main | Wells Fargo | Overweight → Overweight | $14 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-07-23 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-05-16 | down | UBS | Buy → Neutral | $2 |
| 2025-05-12 | main | Goldman Sachs | Buy → Buy | $8 |
| 2025-05-12 | main | Mizuho | Outperform → Outperform | $10 |
| 2025-05-12 | main | Barclays | Overweight → Overweight | $4 |
| 2025-05-09 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-04-17 | main | Goldman Sachs | Buy → Buy | $16 |
| 2025-04-14 | main | Barclays | Overweight → Overweight | $5 |
| 2025-03-03 | main | Truist Securities | Buy → Buy | $15 |
| 2025-03-03 | main | Goldman Sachs | Buy → Buy | $19 |
| 2025-03-03 | main | Chardan Capital | Buy → Buy | $30 |
- Iovance Biotherapeutics stock rating upgraded on revenue growth - Investing.com Wed, 25 Feb 2026 09
- Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits ue, 24 Feb 2026 19
- Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive - Yahoo Finance Mon, 23 Feb 2026 14
- 1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits - The Motley Fool Mon, 23 Feb 2026 08
- Iovance: Better Gross Margin And Faster Turnaround Support Higher Floor (NASDAQ:IOVA) - Seeking Alpha ue, 24 Feb 2026 20
- IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? - Yahoo Finance ue, 24 Feb 2026 14
- Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance ue, 24 Feb 2026 14
- After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits Wed, 25 Feb 2026 07
- One-time cell therapy shrinks tough sarcomas in early Iovance trial - Stock Titan ue, 24 Feb 2026 12
- Earnings call transcript: Iovance Biotherapeutics Q4 2025 sees revenue beat, stock surges - Investing.com ue, 24 Feb 2026 14
- Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) - Seeking Alpha ue, 24 Feb 2026 20
- IOVA Iovance Biotherapeutics (NASDAQ) up 32.06% after Q4 beat 24 Feb 2026: Lifileucel sarcoma data shifts outlook - Meyka ue, 24 Feb 2026 19
- Iovance Biotherapeutics Q4 Loss Narrows To US$0.18 EPS And Tests Bearish Narratives - simplywall.st Wed, 25 Feb 2026 09
- IOVANCE BIOTHERAPEUTICS ($IOVA) Releases Q4 2025 Earnings - Quiver Quantitative ue, 24 Feb 2026 12
- IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? - Zacks Investment Research ue, 24 Feb 2026 13
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 39996 | — | — | KIRBY DANIEL GORDON | Officer | — | 2026-02-10 00:00:00 | D | nan |
| 1 | 12305 | — | — | BILINSKY IGOR P | Chief Operating Officer | — | 2025-12-02 00:00:00 | D | nan |
| 2 | 52086 | — | — | VOGT FREDERICK G | Chief Executive Officer | — | 2025-12-02 00:00:00 | D | nan |
| 3 | 12695 | — | — | GRAF FINCKENSTEIN FRIEDRICH | Officer | — | 2025-12-02 00:00:00 | D | nan |
| 4 | 5469 | — | — | PURI RAJ K | Officer | — | 2025-12-01 00:00:00 | D | nan |
| 5 | 12306 | — | — | BILINSKY IGOR P | Chief Operating Officer | — | 2025-09-02 00:00:00 | D | nan |
| 6 | 52086 | — | — | VOGT FREDERICK G | Chief Executive Officer | — | 2025-09-02 00:00:00 | D | nan |
| 7 | 12697 | — | — | GRAF FINCKENSTEIN FRIEDRICH | Officer | — | 2025-09-02 00:00:00 | D | nan |
| 8 | 5470 | — | — | PURI RAJ K | Officer | — | 2025-09-02 00:00:00 | D | nan |
| 9 | 30000 | — | Purchase at price 1.84 per share. | KIRBY DANIEL GORDON | Officer | — | 2025-06-05 00:00:00 | D | 55200.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.01 | 0.00 | 0.00 |
| NormalizedEBITDA | -351.67M | -427.43M | -377.74M | -328.72M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -372.18M | -444.04M | -395.89M | -342.25M |
| ReconciledDepreciation | 43.61M | 33.13M | 21.14M | 13.98M |
| ReconciledCostOfRevenue | 124.00M | 10.76M | 0.00 | 0.00 |
| EBITDA | -351.67M | -427.43M | -377.74M | -328.72M |
| EBIT | -395.28M | -460.56M | -398.88M | -342.70M |
| NetInterestIncome | 20.27M | 13.04M | 2.98M | 451.00K |
| InterestIncome | 20.27M | 13.04M | 2.98M | 451.00K |
| NormalizedIncome | -372.18M | -444.04M | -395.89M | -342.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -372.18M | -444.04M | -395.89M | -342.25M |
| TotalExpenses | 559.35M | 461.75M | 398.88M | 342.70M |
| TotalOperatingIncomeAsReported | -395.28M | -460.56M | -398.88M | -342.70M |
| DilutedAverageShares | 289.88M | 235.13M | 159.26M | 153.41M |
| BasicAverageShares | 289.88M | 235.13M | 159.26M | 153.41M |
| DilutedEPS | -1.28 | -1.89 | -2.49 | -2.23 |
| BasicEPS | -1.28 | -1.89 | -2.49 | -2.23 |
| DilutedNIAvailtoComStockholders | -372.18M | -444.04M | -395.89M | -342.25M |
| NetIncomeCommonStockholders | -372.18M | -444.04M | -395.89M | -342.25M |
| NetIncome | -372.18M | -444.04M | -395.89M | -342.25M |
| NetIncomeIncludingNoncontrollingInterests | -372.18M | -444.04M | -395.89M | -342.25M |
| NetIncomeContinuousOperations | -372.18M | -444.04M | -395.89M | -342.25M |
| TaxProvision | -2.83M | -3.48M | 0.00 | 0.00 |
| PretaxIncome | -375.00M | -447.52M | -395.89M | -342.25M |
| NetNonOperatingInterestIncomeExpense | 20.27M | 13.04M | 2.98M | 451.00K |
| InterestIncomeNonOperating | 20.27M | 13.04M | 2.98M | 451.00K |
| OperatingIncome | -395.28M | -460.56M | -398.88M | -342.70M |
| OperatingExpense | 435.35M | 450.99M | 398.88M | 342.70M |
| ResearchAndDevelopment | 282.34M | 344.08M | 294.78M | 259.04M |
| SellingGeneralAndAdministration | 153.02M | 106.92M | 104.10M | 83.66M |
| GeneralAndAdministrativeExpense | 104.10M | 83.66M | ||
| OtherGandA | 104.10M | 83.66M | ||
| GrossProfit | 40.08M | -9.57M | 0.00 | 0.00 |
| CostOfRevenue | 124.00M | 10.76M | 0.00 | 0.00 |
| TotalRevenue | 164.07M | 1.19M | 0.00 | 0.00 |
| OperatingRevenue | 164.07M | 1.19M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 305.25M | 256.14M | 187.81M | 157.00M |
| ShareIssued | 305.25M | 256.14M | 187.81M | 157.00M |
| TotalDebt | 58.26M | 75.86M | 85.45M | 71.53M |
| TangibleBookValue | 428.00M | 355.35M | 499.63M | 621.66M |
| InvestedCapital | 711.40M | 585.61M | 500.63M | 622.66M |
| WorkingCapital | 334.68M | 197.54M | 387.63M | 418.76M |
| NetTangibleAssets | 428.01M | 355.36M | 499.64M | 621.66M |
| CapitalLeaseObligations | 57.26M | 74.86M | 84.45M | 70.53M |
| CommonStockEquity | 710.40M | 584.61M | 499.63M | 621.66M |
| PreferredStockEquity | 3.00K | 3.00K | 3.00K | 3.00K |
| TotalCapitalization | 711.40M | 585.61M | 500.64M | 622.66M |
| TotalEquityGrossMinorityInterest | 710.40M | 584.61M | 499.64M | 621.66M |
| StockholdersEquity | 710.40M | 584.61M | 499.64M | 621.66M |
| GainsLossesNotAffectingRetainedEarnings | -1.05M | 2.53M | -902.00K | -601.00K |
| OtherEquityAdjustments | -1.05M | 2.53M | -902.00K | -601.00K |
| RetainedEarnings | -2.38B | -2.01B | -1.57B | -1.17B |
| AdditionalPaidInCapital | 3.10B | 2.59B | 2.07B | 1.79B |
| CapitalStock | 16.00K | 14.00K | 11.00K | 10.00K |
| CommonStock | 13.00K | 11.00K | 8.00K | 7.00K |
| PreferredStock | 3.00K | 3.00K | 3.00K | 3.00K |
| TotalLiabilitiesNetMinorityInterest | 200.02M | 195.74M | 164.34M | 155.67M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 77.68M | 85.43M | 72.86M | 66.47M |
| NonCurrentDeferredLiabilities | 32.31M | 17.35M | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 32.31M | 17.35M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 45.37M | 68.08M | 72.86M | 66.47M |
| LongTermCapitalLeaseObligation | 44.37M | 67.08M | 71.86M | 65.47M |
| LongTermDebt | 1.00M | 1.00M | 1.00M | 1.00M |
| CurrentLiabilities | 122.34M | 110.31M | 91.48M | 89.20M |
| CurrentDebtAndCapitalLeaseObligation | 12.90M | 7.78M | 12.59M | 5.06M |
| CurrentCapitalLeaseObligation | 12.90M | 7.78M | 12.59M | 5.06M |
| PayablesAndAccruedExpenses | 109.44M | 102.53M | 78.90M | 84.14M |
| CurrentAccruedExpenses | 81.94M | 69.41M | 52.30M | 56.77M |
| Payables | 27.51M | 33.12M | 26.60M | 27.38M |
| AccountsPayable | 27.51M | 33.12M | 26.60M | 27.38M |
| TotalAssets | 910.43M | 780.35M | 663.98M | 777.33M |
| TotalNonCurrentAssets | 453.41M | 472.50M | 184.87M | 269.38M |
| OtherNonCurrentAssets | 6.73M | 66.70M | 6.62M | 7.87M |
| InvestmentsAndAdvances | 0.00 | 91.59M | ||
| InvestmentinFinancialAssets | 0.00 | 91.59M | ||
| AvailableForSaleSecurities | 91.59M | |||
| GoodwillAndOtherIntangibleAssets | 282.40M | 229.26M | 0.00 | |
| NetPPE | 164.28M | 176.54M | 178.25M | 169.92M |
| AccumulatedDepreciation | -36.02M | -27.91M | -16.72M | -8.69M |
| GrossPPE | 200.30M | 204.46M | 194.97M | 178.61M |
| Leases | 67.38M | 76.80M | 74.31M | 57.82M |
| ConstructionInProgress | 34.94M | 24.10M | 9.12M | 35.78M |
| OtherProperties | 86.67M | 91.64M | 101.10M | 81.85M |
| MachineryFurnitureEquipment | 11.32M | 11.92M | 10.44M | 3.16M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 457.02M | 307.85M | 479.12M | 507.96M |
| OtherCurrentAssets | 12.38M | 17.46M | 7.27M | 3.55M |
| PrepaidAssets | 3.55M | |||
| Inventory | 51.52M | 10.37M | 0.00 | |
| FinishedGoods | 15.01M | 4.62M | 0.00 | |
| WorkInProcess | 8.77M | 5.75M | 0.00 | |
| RawMaterials | 27.74M | 0.00 | ||
| Receivables | 69.34M | 151.00K | 0.00 | |
| AccountsReceivable | 69.34M | 151.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 323.78M | 279.87M | 471.85M | 504.41M |
| OtherShortTermInvestments | 208.09M | 164.98M | 240.11M | 426.18M |
| CashAndCashEquivalents | 115.69M | 114.89M | 231.73M | 78.23M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -364.05M | -384.11M | -313.18M | -265.51M |
| IssuanceOfDebt | 0.00 | 0.00 | 1.00M | |
| IssuanceOfCapitalStock | 397.30M | 463.28M | 189.50M | 203.16M |
| CapitalExpenditure | -11.07M | -22.29M | -20.43M | -37.57M |
| EndCashPosition | 122.05M | 181.32M | 238.16M | 84.31M |
| BeginningCashPosition | 181.32M | 238.16M | 84.31M | 72.85M |
| EffectOfExchangeRateChanges | -541.00K | -2.74M | ||
| ChangesInCash | -58.72M | -54.10M | 153.85M | 11.46M |
| FinancingCashFlow | 390.66M | 462.96M | 190.15M | 239.27M |
| CashFlowFromContinuingFinancingActivities | 390.66M | 462.96M | 190.15M | 239.27M |
| NetOtherFinancingCharges | -12.86M | -2.79M | -2.65M | |
| ProceedsFromStockOptionExercised | 6.22M | 2.47M | 3.30M | 35.11M |
| NetCommonStockIssuance | 397.30M | 463.28M | 189.50M | 203.16M |
| CommonStockIssuance | 397.30M | 463.28M | 189.50M | 203.16M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 1.00M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 1.00M | |
| LongTermDebtIssuance | 0.00 | 0.00 | 1.00M | |
| InvestingCashFlow | -96.41M | -155.24M | 256.45M | 132.00K |
| CashFlowFromContinuingInvestingActivities | -96.41M | -155.24M | 256.45M | 132.00K |
| NetInvestmentPurchaseAndSale | -32.77M | 79.68M | 276.88M | 37.71M |
| SaleOfInvestment | 428.00M | 285.58M | 522.70M | 762.91M |
| PurchaseOfInvestment | -460.77M | -205.90M | -245.82M | -725.21M |
| NetBusinessPurchaseAndSale | -52.57M | -212.63M | 0.00 | 0.00 |
| PurchaseOfBusiness | -52.57M | -212.63M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -11.07M | -22.29M | -20.43M | -37.57M |
| PurchaseOfPPE | -11.07M | -22.29M | -20.43M | -37.57M |
| OperatingCashFlow | -352.98M | -361.82M | -292.76M | -227.94M |
| CashFlowFromContinuingOperatingActivities | -352.98M | -361.82M | -292.76M | -227.94M |
| ChangeInWorkingCapital | -122.56M | -6.52M | -2.89M | 24.55M |
| ChangeInOtherCurrentLiabilities | -12.07M | -10.79M | -1.94M | -5.88M |
| ChangeInPayablesAndAccruedExpense | 737.00K | 24.60M | 1.18M | 27.66M |
| ChangeInAccruedExpense | 8.58M | 19.77M | -4.70M | 20.68M |
| ChangeInPayable | -7.84M | 4.83M | 5.88M | 6.98M |
| ChangeInAccountPayable | -7.84M | 4.83M | 5.88M | 6.98M |
| ChangeInPrepaidAssets | -2.11M | -10.06M | -2.13M | 2.77M |
| ChangeInInventory | -39.92M | -10.12M | 0.00 | 0.00 |
| ChangeInReceivables | -69.19M | -149.00K | 0.00 | 0.00 |
| ChangesInAccountReceivables | -69.19M | -149.00K | 0.00 | 0.00 |
| StockBasedCompensation | 109.63M | 62.62M | 84.02M | 69.77M |
| AssetImpairmentCharge | 7.36M | 0.00 | 397.00K | 0.00 |
| AmortizationOfSecurities | -10.26M | -3.60M | 474.00K | 6.01M |
| DeferredTax | -2.83M | -3.48M | 0.00 | 0.00 |
| DeferredIncomeTax | -2.83M | -3.48M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 43.61M | 33.13M | 21.14M | 13.98M |
| DepreciationAndAmortization | 43.61M | 33.13M | 21.14M | 13.98M |
| AmortizationCashFlow | 21.20M | 9.85M | 0.00 | 0.00 |
| AmortizationOfIntangibles | 21.20M | 9.85M | 0.00 | 0.00 |
| Depreciation | 22.40M | 23.28M | 21.14M | 13.98M |
| OperatingGainsLosses | -5.74M | 70.00K | ||
| NetForeignCurrencyExchangeGainLoss | -175.00K | 70.00K | 0.00 | 0.00 |
| GainLossOnSaleOfPPE | -5.57M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -372.18M | -444.04M | -395.89M | -342.25M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IOVA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|